Istituto di Chimica Biomolecolare del CNR, Traversa La Crucca 3, Li Punti, Sassari I-07100, Italy.
Curr Med Chem. 2010;17(13):1255-99. doi: 10.2174/092986710790936301.
The outstanding physio-pathological role played by integrin receptors in living subjects motivates the enormous interest shown by scientists worldwide for this topic. More than twenty years of research has spanned across the structural and functional elucidation of these proteins and over their antagonism-based biomedical applications. The proof-of concept stage, aimed at identifying potent inhibitors, covered a decade of studies, and paved the way for a more advanced era of research where these antagonist molecules were thrown into the deep end of applicative studies. This review intends to summarize the major efforts conducted thus far and focuses on the design, synthesis and biomedical applications of cyclic RGD-containing alpha(v)beta(3) integrin antagonists, in both their small and macromolecular formats. In particular, Chapters 1 and 2 offer a comprehensive outlook on the rational basis for the design of integrin inhibitors, Chapter 3 chronicles the biological and medical applications of monofunctional RGD integrin ligands both in their monomeric and multimeric asset, and Chapter 4 illustrates the potential of RGD-based multifunctional systems in molecular medicine.
整合素受体在活体中发挥的突出生理病理作用激发了全球科学家对此课题的巨大兴趣。二十多年的研究涵盖了这些蛋白质的结构和功能阐明及其基于拮抗作用的生物医学应用。旨在确定有效抑制剂的概念验证阶段涵盖了十年的研究,为更先进的研究时代铺平了道路,这些拮抗剂分子被投入到应用研究的深水区。本篇综述旨在总结迄今为止的主要研究成果,并重点介绍含环 RGD 的α(v)β(3)整合素拮抗剂的设计、合成和生物医学应用,包括小分子和大分子两种形式。具体来说,第 1 章和第 2 章全面概述了整合素抑制剂设计的合理依据,第 3 章记载了单功能 RGD 整合素配体在单体和多聚体形式中的生物学和医学应用,第 4 章说明了基于 RGD 的多功能系统在分子医学中的潜力。